The Claim

The human monoclonal autoantibody K1-70TM binds to the thyroid-stimulating hormone receptor with high affinity, inhibits stimulation by thyroid-stimulating hormone and pathogenic autoantibodies, and results in reduced thyroid hormone production and improvement in Graves' ophthalmopathy in a single patient and early-phase clinical trial.

Source: Autoantibodies to the TSH Receptor—from discovery to understanding the mechanisms of action and to new therapeutics

What the research says

Roughly balanced

Support and challenge are close. The picture may shift as more studies come in.

Supports
1score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

The antibody K1-70TM attaches to the thyroid-stimulating hormone receptor and prevents both thyroid-stimulating hormone and harmful autoantibodies from activating it, leading to lower thyroid hormone levels and reduced eye inflammation in Graves' ophthalmopathy in one patient and an early clinical trial.

See the scientific wording

The human monoclonal autoantibody K1-70TM binds to the thyroid-stimulating hormone receptor with high affinity and blocks stimulation by TSH and pathogenic autoantibodies, leading to reduced thyroid hormone production and improvement in Graves' ophthalmopathy in a single patient and early-phase clinical trial.

Why this might work

A special antibody called K1-70TM attaches to a specific spot on the thyroid control switch, physically blocking thyroid-stimulating hormone and harmful antibodies from binding. This stops the switch from turning on, which prevents the thyroid from making too much hormone and reduces swelling in the eyes.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Autoantibodies to the TSH Receptor—from discovery to understanding the mechanisms of action and to new therapeutics

    Scientists made a special antibody called K1-70TM that sticks to the thyroid’s control switch and stops harmful antibodies from overactivating it. This helped reduce eye swelling in people with Graves’ disease during early testing.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.